Shanghai Fosun Pharmaceutical (02196): The drug registration application for sodium phosphonoformate injection has been approved by the National Medical Products Administration.

Shanghai Fosun Pharmaceutical (02196) announced that its holding subsidiary Guilin Nan Pharm Co., Ltd. has received approval from the National Medical Products Administration for the drug registration application of Sodium Foscarnet Injection. The approved indications for this drug include treatment of (1) Cytomegalovirus retinitis in patients with AIDS, and (2) Herpes simplex virus skin and mucous membrane infections in immunocompromised patients. As of November 2025, the total research and development investment by the group (including the company and its holding subsidiaries/units) for this drug is approximately RMB 4.98 million (unaudited). According to the latest data from IQVIA CHPA, the sales of Sodium Foscarnet Injection in China (excluding Hong Kong, Macao, and Taiwan) in 2024 were approximately RMB 86.4 million. The approval of this drug for market will further enrich the product line of the group.